Although prespecified stopping guidelines were not met, a negative trend in long-term mortality prompted the DSMB to recommend suspension of enrollment and discontinuation of study drug [ 9 ].
← all excerpts
Clinical Utility of the Sivelestat for the Treatment of ALI/ARDS: Moving on in the Controversy?
1
—
—